BioNTech has seen its share price rise by 25% in the last few days, buoyed by new investor belief in its emerging cancer drugs pipeline.
ESMO 24: Investors Are Starting To Believe In BioNTech’s Cancer Drugs
The company’s investment in oncology is starting to pay off, with its PD-L1/VEGF inhibitor BNT324 generating particular interest at ESMO.
